

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/93558/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Williams, Anwen , Wang, Edward Chung Yern , Thurner, Lorenz and Liu, Chuan-ju 2016. Novel insights into TNF receptor, DR3 and progranulin pathways in arthritis and bone remodeling. *Arthritis & Rheumatology* 68 (12) , pp. 2845-2856.
10.1002/art.39816

Publishers page: <http://dx.doi.org/10.1002/art.39816>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Novel insights into TNF receptor, DR3 and progranulin pathways in arthritis and bone remodeling

Anwen Williams, PhD^{1,¶}, Eddie C. Y. Wang, PhD², Lorenz Thurner, MD³, Chuan-ju Liu, PhD^{4,¶}

From ¹Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK; Arthritis Research UK Centre for Biomechanics and Bioengineering, Cardiff University, Cardiff, UK; ²Department of Medical Microbiology & Infectious Disease, Institute of Infection & Immunity, Cardiff University School of Medicine, Cardiff, UK; ³Saarland University Medical School, José Carreras Center for Immuno- and Gene Therapy, Internal Medicine I, Homburg, Saar, Germany; ⁴Department of Orthopaedic Surgery, New York University Medical Center, New York, NY10003; Department of Cell Biology, New York University School of Medicine, New York, NY 10016

[¶]To whom correspondence should be addressed: Dr. Anwen Williams, Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK; Tel: 44(0)29 20687092; Email: williamsas@cf.ac.uk; or Dr. Chuan-ju Liu, Department of Orthopaedic Surgery, New York University Medical Center. Tel: 212-598-6103; Email: chuanju.liu@med.nyu.edu

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an 'Accepted Article', doi: 10.1002/art.39816

© 2016 American College of Rheumatology

Received: Jan 29, 2016; Revised: May 22, 2016; Accepted: Jul 12, 2016

Introduction

About 30 members of tumor necrosis factor receptor superfamily (TNFRSF) have been identified. They are transmembrane proteins with cysteine-rich motifs in their extracellular domains that bind to their cognate ligands [1]. They are categorized into three groups; death domain-containing receptors, decoy receptors, and TNF receptor-associated factor-binding receptors. Only eight TNFRSF members contain a death domain (TNFR1, DR3, DR4, DR5, DR6, Fas, NGFR, EDAR) of which TNFR1 and DR3 constitute the principle focus of this article. Interactions between tumor necrosis factor superfamily (TNFSF) ligands and TNFRSF receptors help maintain tissue homeostasis by controlling survival, proliferation, differentiation, and effector function of immune cells. Here the authors limit their review to recent advances and novel insights into the role of TNFR1 and DR3 in bone and joint biology.

Bone cells (osteoblasts, osteoclasts and osteocytes), fibroblast-like synoviocytes, chondrocytes and immune cells that infiltrate the arthritic joint will at different times express a wide range of TNFRSF members and TNFSF ligands. An overview of the current status of our knowledge in this regard is provided in **Table 1**. The impact of TNFR1 activation on bone and inflammatory joint diseases has been researched in great depth [2, 3], but other more recently discovered TNFRSF members such as TROY, EDAR and XEDAR have little or no published data in the field. The unexpected interaction between Progranulin (PGRN) and both TNFR1 and TNFR2 is particularly interesting in the context of arthritis-associated bone pathology. PGRN levels are elevated in synovial fluid of patients with rheumatoid arthritis, osteoarthritis and other arthropathies [4-6], and it has been shown to inhibit TNF α -induced osteoclastogenesis and promotes osteoblast differentiation in mice [7]. However, PGRN has a higher binding affinity for TNFR2 (anti-inflammatory with osteoprotective function) than TNFR1 (predominantly pro-

inflammatory with degenerative function) suggesting conflicting actions. The potential overall impact of these divergent PGRN signaling pathways upon the architecture of the arthritic joint are evaluated [8].

Death receptor (DR3) and its TNFSF ligand TL1A contribute to the pathogenesis of autoimmune and rheumatic diseases [9], however, research in this area is very much in its infancy. Inhibition of DR3 reduces osteoclastogenesis and protects bones against the development of erosive pathology in experimental models of arthritis [10]. A soluble form of DR3, produced by osteoblasts, regulates osteoblast apoptosis under tightly controlled conditions [11, 12]. TL1A levels are elevated in serum from patients with rheumatoid arthritis versus healthy controls. This review provides further insight to DR3's role in bone remodeling and arthritis.

PGRN/TNFR interactions in arthritis and bone remodeling

PGRN, also known as granulins–epithelin precursor (GEP), proepithelin, acrogranin, and GP88/PC-cell derived growth factor (PCDGF), is a 593-amino-acid autocrine growth factor. PGRN contains seven-and-a-half repeats of a cysteine-rich motif (CX5–6CX5CCX8CCX6CCXDX2HCCPX4CX5–6C) and forms a unique “beads-on-a-string” structure [13]. PGRN was first found to bind to TNFR in a yeast two-hybrid screening for PGRN-binding proteins [14]. The interaction was subsequently validated in human cells. Surface plasmon resonance (SPR) analysis revealed that PGRN bound to both TNFR1 and TNFR2 and with greater affinity than TNF α to TNFR2 [8, 14]. Three fragments of PGRN and their adjacent linkers enable the ligand to bind to TNF receptors [15]. Notably, PGRN showed therapeutic effects in several TNF-mediated inflammatory arthritis models, including collagen-induced

arthritis, collagen antibody induced arthritis, and spontaneous arthritis in the TNF-transgenic mouse model [14, 16, 17]. Furthermore a novel PGRN-mimetic called Atsttrin (**Fig. 1**) had a more pronounced beneficial effects than PGRN on inflammatory arthritis [14]. Currently marketed anti-TNF therapies bind to the TNF α ligand, in contrast, Atsttrin binds to TNFR and not to TNF α itself. Atsttrin was more efficacious than current anti-TNF α therapies, including etanercept, in several preclinical inflammatory arthritis models tested [14].

Accumulating evidence indicates that TNF α orchestrates osteoarthritis (OA) pathology [18]. Recent finding support the notion that PGRN could also modulate the aetiopathogenesis of OA. PGRN is an important regulator of cartilage development [19, 20], was identified as an OA-associated growth factor in a genome-wide screen for differentially expressed genes in OA [21], and in aging mice PGRN deficiency led to spontaneous OA-like phenotype characterized by severe breakdown of cartilage structure[22]. The OA-like pathology was attenuated by the local delivery of a recombinant PGRN protein. Intra-articular transplantation of Atsttrin-transduced mesenchymal stem cells inhibited TNF α -mediated catabolic response, ameliorating OA development [23]. One chondro-protective mechanism has been proposed, namely that PGRN increased the levels of anabolic biomarkers and suppresses inflammatory action of TNF α in cartilage and chondrocytes via activation of the ERK1/2 signaling pathway[19].

The direct impact of PGRN upon bone remodeling is yet to be determined, with current knowledge derived from a bone-healing model. In mice at least, PGRN deficiency delayed bone healing, while recombinant PGRN enhanced bone regeneration [24]. Furthermore, PGRN-mediated bone formation was dependent upon TNFR2, but not TNFR1. In this same study, Zhao et al showed that PGRN blocked osteoclastogenesis in TNF- α transgenic mice. Taken together these findings imply that PGRN exerts dual action on bone during inflammatory arthritis namely;

inhibiting TNF- α induced bone erosion by osteoclasts and promoting osteoblast-dependent mineral apposition via a TNFR2. A recent report using Atsttrin, incorporated into 3D-printed alginate/hydroxyapatite scaffolds, implies that PGRN stimulates bone regeneration by inhibiting TNF signaling [25].

TNF α 's inflammatory and catabolic actions are largely mediated through its interaction with TNFR1. However, understanding of the impact of TNFR2-mediated signaling remains largely unclear. Recent studies indicate that TNFR2 signaling has a beneficial and protective role in joint destruction [26, 27]. Studies also reveal differential roles of TNFR1 and TNFR2 in PGRN-mediated fracture healing and OA [22, 24, 28]. Although PGRN and TNF α exhibit comparable binding affinity to TNFR1, PGRN has an approximately 600-fold higher binding affinity for TNFR2 than TNF α [14]. Since PGRN and TNF α compete for binding to the same extracellular cysteine-rich domains (CRD) of TNFR, CRD2 and CRD3 [8], PGRN acts as a naturally-occurring antagonist of TNF α and disturbs the binding of TNF α to TNFRs. More importantly, PGRN also acts as a ligand of TNFR2 and directly activates the PGRN/TNFR2 protective and anti-inflammatory pathway. TNFR2 has been shown to be critical for PGRN-mediated protection in OA and bone fracture healing [22, 24, 28]. Recent paper showing that local injection of soluble TNFR2 (sTNFR2, etanercept) resulted in more severe joint destruction in a mouse model of OA [29] also suggest the importance of PGRN-mediated protection in OA. Injection of sTNFR2 inhibits both TNF α and PGRN. Further, PGRN may be more inhibited than TNF α , as PGRN has a much higher binding affinity to TNFR2 than TNF α . Unlike etanercept, mouse TNF α monoclonal antibody (infliximab) and humanized TNF α monoclonal antibody (adalimumab) are specific for TNF α , and have been shown to be protective against OA in animal models [30]. The opposite effects of TNF α specific (i.e. infliximab and adalimumab) and non-

specific (i.e. etanercept) inhibitors in OA indicate the critical protective role of other ligand(s) of TNFR, i.e. PGRN, in the pathogenesis of OA [31]. Thus, future studies are warranted to clarify the complex interplay between TNF α , PGRN and their receptors in the pathogenesis of arthritis and bone remodeling, which will not only better our understanding of TNFR signaling in the pathogenesis of these musculoskeletal disorders, but may lead to innovative therapies via selectively targeting distinct TNFR pathways.

TL1A/DR3 interactions in arthritis and bone remodeling

Death Receptor 3 (DR3, TNFRSF25, Apo3, LARD, TR3, TRAMP, WSL-1) was discovered simultaneously in the mid-to-late 1990s by multiple groups, when a combination of BLAST homology searches to Fas and TNFR1 [32, 33] and a yeast-two hybrid library screen using a TNFR1 death domain as bait [34], identified a closely related protein. Subsequently, DR3 emerged as the closest structural homolog to TNFR1, containing an equivalent 4 CRDs as well as an intracellular death domain. Unlike TNFR1, however, whose cellular distribution is widespread and surface expression of which is controlled by the generation of soluble forms through cleavage, DR3 has a more restricted tissue distribution and is regulated by the expression of multiple activation-induced splice variants, including soluble and death-domain containing transmembrane forms with excision of the membrane proximal CRD [33, 35]. The exact function of these splice variants remain unclear.

The identification of ligand(s) for DR3 has been complicated by the number of potential candidates and their altering nomenclature [36], but prior to the discovery of PGRN, one TNFSF member, TNF-like protein 1A (TL1A, TNFSF15) [37], had withstood stringent biochemical and

functional scrutiny for DR3 specificity [38, 39]. TL1A is the product of a longer alternative mRNA transcript to a protein initially named vascular endothelial growth inhibitor or VEGI (TL1), so named for its capacity to inhibit angiogenesis and induce apoptosis of endothelial cells [40]. As its name and nomenclature suggests, TL1A is closely related in structure to TNF α , encoding a type II transmembrane protein with a metalloprotease cleavage site allowing release of a soluble molecule, but also has distinct expression patterns as it is found in ng/ml concentrations in serum from healthy individuals [41] that suggests physiologically different levels of production and functional regulation. In this regard, there may also be significant differences between species as DcR3, the decoy ligand for TL1A, FasL and LIGHT (discussed above), is only found in man and not mouse. It is in this context that interpretations of DR3 function and its potential for therapy should be taken.

The generation of transgenic mice genetically deficient for DR3, TL1A or overexpressing TL1A or dominant negative forms of DR3 have given rise to many *in vivo* studies describing the essential requirement for the DR3/TL1A pathway in models of multiple autoimmune and inflammatory diseases. These have supported an ever-growing list of *in vitro* human functional and genetic studies that have associated DR3 and TL1A with human diseases ranging from inflammatory bowel disease and primary biliary cirrhosis to leprosy (comprehensively reviewed in [42]). Of significance for this review were findings that suggested alternate respective ligands for DR3 and TL1A. This included the apparent greater protection against experimental autoimmune encephalomyelitis afforded by DR3^{-/-} [38] compared to TL1A^{-/-} mice [43] in otherwise similar models of disease and the DR3-independent triggering of TNFR2 expression by TL1A in kidney organ cultures [44]. The underlying conclusion was that there were still

unknown interactions for this complex of proteins, which will have to be discovered and dissected in detail before their full potential as therapeutic targets can be understood.

With specific regard to disorders of the bone, initial genetic studies suggested DR3 gene duplication [45] and a mutation predicted to destabilize DR3 [46] were linked to development of rheumatoid arthritis (RA), while synovial cells from RA patients exhibited a hypermethylated DR3 gene suggestive of activation [47], however, genome wide association studies (GWAS) have had less success with supporting this connection. Two early investigations associated genetic variation around the DR3 (TNFRSF25) locus with RA [48, 49], but more recent ones have not. In contrast, genetic variation at the TL1A (TNFSF15) locus has not been associated with RA, but has been linked to another bone disorder, ankylosing spondylitis [50]. Irrespective, increased levels of TL1A have been reported in the serum of patients suffering from both of these arthritides [41, 51, 52], as well as the synovial tissue and synovial exudates of rheumatoid factor positive RA patients [53, 54].

The functional consequences of raised TL1A levels in these disorders have generally been associated with a range of outcomes dependent on the type and differentiation state of the DR3-expressing cell to which TL1A is binding and signaling. Here, we will cover those cell types specifically associated with bone physiology irrespective of the inflammatory context, although it should be noted that there may also be secondary effects as TL1A can induce TNF α [55], thereby having the capacity to trigger a broad range of secondary effects associated with other pro-inflammatory cytokines. The DR3/TL1A axis was first described as a T cell co-stimulator [37], but its effects on Th17 cells, drivers of osteoclastogenesis and therefore inflammatory bone resorption [56], highlighted the complexity in the outcome of TL1A signaling. Initial reports in TL1A^{-/-} mice suggested that TL1A regulated Th17 differentiation [43], but more extensive *in*

vitro studies in both DR3^{-/-} mice [57] and healthy human subjects indicated that Th17 differentiation from naïve CD4⁺ T cells was impaired, while maintenance of the response once T cells were Th17 committed was enhanced, by TL1A [58]. Intriguingly, recent reports have shown that TL1A-driven Th17 differentiation from naïve CD4⁺ T cells occurs in samples from RA patients [52, 59]. Why these differences have been observed remain an area of debate, though the underlying theme is that TL1A promotes the Th17 response in RA.

The development of the main effectors of bone resorption, osteoclasts, are also regulated by the DR3/TL1A axis, at least in an inflammatory setting. While osteoclastogenesis driven by M-CSF and RANK-L was unaffected in DR3^{-/-} mice, these animals exhibited resistance to cartilage destruction and bone erosions in a model of antigen-induced arthritis (AIA) [39, 60]. Furthermore, DR3^{-/-} mice were resistant to exacerbation induced by exogenous addition of TL1A, while antagonism of the pathway with anti-TL1A mAb ameliorated disease in collagen-induced arthritis (CIA) [39]. Addition of exogenous TL1A also exacerbated CIA [54]. The direct nature of this signaling in myeloid cells has been demonstrated, with DR3 expression being induced during the process of macrophage differentiation and TL1A signaling resulting in the DR3-dependent production of the gelatinase MMP-9 [61]. The DR3/TL1A pathway may also control other aspects of macrophage differentiation that promote the arthritic process. Thus, DR3 regulates the expression of scavenger receptors on macrophages [62], which have been implicated in AIA-induced cartilage destruction [63].

Finally, DR3 also modulates osteoblast function. Human osteoblast cell lines were first reported to express DR3 in 2003 [64], which were then used to demonstrate differential regulation dependent on cell culture conditions. Crosslinking induced apoptosis at low density, but differentiation at high density [11]. The subsequent reported association between TL1A and

ankylosing spondylitis [50] and breeding of the DR3^{-/-} genotype on a DBA/1 background, which spontaneously develops ankylosing enthesopathy [65], led to a recent study on the role of DR3 in osteoblast function *in vitro* and *in vivo*. Indeed, DBA/1 DR3^{-/-} mice showed significantly lower thoracic spine-specific bone formation *in vivo*, while DR3^{-/-} osteoblast cultures exhibited reduced levels of alkaline phosphatase, osteopontin and mineral apposition [12]. Thus, the DR3/TL1A axis is involved in the direct regulation of every major cell type involved in bone physiology, recent data suggesting it has an important homeostatic role in this tissue as well as its more established function in inflammatory disease.

PGRN/DR3 Interactions in arthritis and bone remodeling

Screening the associations of Atsttrin with all members of the TNFR subfamily led to the discovery that in addition to TNFR, PGRN/Atsttrin also directly binds to DR3 and inhibits TL1A activity [66]. Structural modeling of DR3 predicts a similar structure to TNFR1 in which primary contacts with TL1A are in the 2nd and 3rd CRD [46]. In addition, a mutation linked to rheumatoid arthritis at the end of CRD3 is in a region critical for structural integrity of ligand–receptor complexes [46]. The first three CRD domains of the extracellular portion of DR3, i.e. CRD1, CRD2 and CRD3, are all required for interacting with Atsttrin. PGRN was also found to directly bind to DR3 in an *in vitro* binding assay, as it did to TNFRs [66]. Atsttrin dose-dependently inhibited TL1A-stimulated expressions of TL1A-target genes C1qTNF3 and β₂M. In addition, Atsttrin effectively neutralized TL1A-promoted osteoclastogenesis *in vitro* [66].

◀ The associations of PGRN with TNFR and DR3 also led to investigations on the immunological mechanisms underlying PGRN mediated anti-inflammatory and protective activities in

autoimmune diseases[67-69]. Since both animal and human studies have demonstrated that regulatory T cells (Tregs) play a critical role in the prevention of autoimmunity and other pathological immune responses, the effects of PGRN on Treg differentiation and function were first determined. PGRN protects Tregs from a negative regulation by TNF α and these protective effects are primarily mediated by TNFR2[68, 69]. In contrast, PGRN-antibodies, opposite to recombinant PGRN, led to an increase of TNF α -induced down-regulation of FOXP3 in CD4⁺CD25^{hi} Tregs [70]. In addition, PGRN was able to stimulate the conversion of CD4⁺CD25⁻ T cells into induced Tregs (iTregs) in a dose-dependent manner *in vitro*. Further, PGRN showed synergistic effects with TGF- β 1 on the induction of iTreg[69]. PGRN was required for the immunosuppressive function of Tregs, since PGRN-deficient Tregs have a significant decreased ability to suppress the proliferation of effector T cells. PGRN deficiency caused a marked reduction in Tregs number in the course of inflammatory arthritis [69]. In a bone marrow chimera and CD4⁺CD45Rb^{hi} T cell transfer model, lack of PGRN signaling in CD4⁺ T cells also exacerbated experimental colitis. In addition, PGRN-mediated protective effect was compromised in the absence of IL-10 or TNFR2 signaling[68]. It is noted that PGRN mediated regulation of Tregs appears to be inflammation-dependent, because PGRN deficiency does not alter the numbers of CD4⁺CD25⁺Foxp3⁺ Treg cells *in vivo* under physiological conditions [69]. Progranulin inhibits expression and release of chemokines CXCL9 and CXCL10 in a TNFR1 dependent manner CD4⁺ T cells [67]. The DR3 pathway may also contribute to PGRN-mediated protective effect in inflammatory diseases, since a recent report showed that agonistic antibody to DR3 expanded CD4(+)FoxP3(+) Tregs *in vivo*, which in turn suppressed immune responses. In addition, a neuropathology develops with age in both DR3^{-/-} [71] and PGRN deficient mice[72]. Intriguingly, transgenic overexpression of TL1A in both the myeloid and T cell

lineage results in *in vivo* expansion of Tregs, though these eventually become dysregulated and intestinal inflammation develops [10].

In contrast to Tregs, Th17 cell frequency was decreased significantly in the spleens of mice treated with recombinant PGRN in a collagen-induced arthritis model [68, 69]. In addition, the serum level of IL-17 was also decreased significantly in PGRN-treated mice. Further, both TNFR1 and DR3 pathways were found to be involved in the PGRN inhibition of IL-17 cells. Taken together, PGRN and its derived Atsttrin appear to exert their anti-inflammatory activities through multiple pathways: **1)** by activation of PGRN/TNFR2 protective pathway, and **2)** by inhibition of TNF/TNFR1 and TL-1A/DR3 inflammatory signaling (**Fig. 2**).

Clinical perspective

Because TNF α is one of the key main inflammatory mediators, it is no surprise that alterations of its physiologic antagonist PGRN have a direct impact on the initiation and progression of arthritis. The effect of TNF α antagonism should be at least comparable to conventional TNF α -blockers [14]. The additional specific inhibition of the TL1A/DR3 interaction and activation of TNFR2 anti-inflammatory pathway by PGRN or its derivate [66] is a unique characteristic and might represent a significant advantage over conventional TNF α inhibitors particularly for patients with refractory or relapsing disease under conventional TNF α -blockers. Blocking the TL1A/DR3 interaction probably offers additional positive effects by the reduction of proinflammatory cytokines, reduction of autoantibody formation and by the reduction of osteoclastogenesis [10, 54].

A potential disadvantage of PGRN or Atsttrin compared to anti-TNF α antibodies might be, that anti-TNF α antibodies can trigger apoptosis of proinflammatory T-lymphocytes by binding to membranous TNF α . This effect, which is also missing for TNFR/Fc fusion proteins, appears to play a particular role in inflammatory bowel diseases (IBD) and less in arthritis [73]. The question is whether the administration of PGRN or a derivative thereof has a higher risk of iatrogenic induced neoplasms than conventional TNF α blockers. Usage of conventional TNF α -blockers results in an elevated risk for reactivation of latent infections such as mycobacteria, viral hepatitis, or for the development of opportunistic infections [74]. The effects of administered recombinant PGRN or its derivative on the risk for opportunistic infections remain speculative and are not further discussed in this review.

Another question arises through the discovery of progranulin-autoantibodies: Can recombinant PGRN or Atsttrin be administered to patients with preexisting PGRN-antibodies? Frequently occurring PGRN antibodies have been identified in a wide spectrum of autoimmune diseases including rheumatoid arthritis and surprisingly psoriatic arthritis, which had been regarded as a seronegative disease [5, 75]. PGRN-antibodies occur in relevant titres, belong predominantly to IgG1 subclass (in IBD also IgA), have a neutralizing effect on PGRN plasma levels and thus are likely to act in a proinflammatory fashion.

Epitope mapping identified a binding region within the N-terminal 112 amino acids of PGRN as a target of progranulin antibodies in all patients. This means that PGRN-autoantibodies target the anti-inflammatory progranulin and possibly co-target only mature granulin G, the most N-terminal granulin motif. Despite the structural similarity of granulin G with the other six granulins, no binding against granulin motifs other than granulin G was detected [75]. With regard to Atsttrin, no antibodies were detected so far directed against those parts of progranulin

which are constitutive of Atsttrin, i.e. granulin F, granulin A, granulin C and the appropriate linker regions [14]. Nevertheless, epitope spreading and immunogenicity should be monitored closely in preclinical and clinical trials addressing the therapeutic effects of Atsttrin administration. A potential binding of patient derived, preexisting PGRN-antibodies against Atsttrin itself has not yet been tested to our knowledge and should be excluded.

As a reason for the breakdown of self-tolerance against PGRN, a second immunogenic PGRN isoform, hyperphosphorylated at Ser81 was exclusively identified in a PGRN-antibody-positive patients [76]. This hyperphosphorylated PGRN is caused by inactivated PP1. Interestingly, the phosphorylation of Ser81 PGRN prevents interaction with TNFR1 & 2 and DR3, so hyperphosphorylated PGRN has lost its anti-inflammatory function. Considering these facts, it seems a reasonable therapeutic strategy would be to compensate the imbalance of pro- and anti-inflammatory molecules due to either lack of functional PGRN, caused by neutralizing PGRN-antibodies, Ser81 hyperphosphorylation of PGRN, and/or excessive secretion of TNF α and TL1A, by the administration of a PGRN derivate, which cannot be neutralized by pre-existing PGRN-autoantibodies (**Fig. 3**).

In conclusion it can be stated that PGRN and its interaction with TNF α /TNFR1&2 and TL1A/DR3 represent an attractive new therapeutic target (**Table 2**). Looking at the underlying theory and the known preclinical data, Atsttrin could be a therapeutic alternative in cases of refractory or recurrent arthritis.

References

1. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, Ambrose C, Tschopp J, Schneider P: Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. *J Biol Chem* 2006, 281(20):13964-13971.
2. Espirito Santo AI, Ersek A, Freidin A, Feldmann M, Stoop AA, Horwood NJ: Selective inhibition of TFNR1 reduces osteoclast numbers as is differentiated from anti-TNF in a LPS-driven model of inflammatory bone loss. *Biochem Biophys Res Commun* 2015, 464:1145-1150.
3. Schling P, Rudolph C, Heimerl S, Fruth S, Schmitz G: Expression of tumor necrosis factor alpha and its receptors during cellular differentiation. *Cytokine* 2013, 33:239-245.
4. Andres Cerezo L, Kuklova M, Hulejova H, Vernerova Z, Kasprikova N, Veigl D, Pavelka K, Vencovsky J, Senolt L: Progranulin Is Associated with Disease Activity in Patients with Rheumatoid Arthritis. *Mediators Inflamm* 2015, 2015:740357.
5. Thurner L, Zaks M, Preuss KD, Fadle N, Regitz E, Ong MF, Pfreundschuh M, Assmann G: Progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritis. *Arthritis Res Ther* 2013, 15(6):R211.
6. Yamamoto Y, Takemura M, Serrero G, Hayashi J, Yue B, Tsuboi A, Kubo H, Mitsuhashi T, Mannami K, Sato M *et al*: Increased serum GP88 (Progranulin) concentrations in rheumatoid arthritis. *Inflammation* 2014, 37(5):1806-1813.
7. Noguchi T, Ebina K, Hirao M, Kawase R, Ohama T, Yamashita S, Morimoto T, Koizumi K, Kitaguchi K, Matsuoka H *et al*: Progranulin plays crucial roles in preserving bone mass by inhibiting TNF-alpha-induced osteoclastogenesis and promoting osteoblastic differentiation in mice. *Biochem Biophys Res Commun* 2015.
8. Jian J, Zhao S, Tian Q, Gonzalez-Gugel E, Mundra JJ, Uddin SM, Liu B, Richbourgh B, Brunetti R, Liu CJ: Progranulin directly binds to the CRD2 and CRD3 of TNFR extracellular domains. *FEBS Lett* 2013, 587(21):3428-3436.
9. Siakavellas SI, Sfrikakis PP, Bamias G: The TL1A/DR3/DcR3 pathway in autoimmune rheumatic diseases. *Seminars in arthritis and rheumatism* 2015, 45(1):1-8.
10. Bull MJ, Williams AS, Mecklenburgh Z, Calder CJ, Twohig JP, Elford C, Evans BA, Rowley TF, Slebioda TJ, Taraban VY *et al*: The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. *J Exp Med* 2008, 205(11):2457-2464.
11. Borysenko CW, Garcia-Palacios V, Griswold RD, Li Y, Iyer AK, Yaroslavskiy BB, Sharrow AC, Blair HC: Death receptor-3 mediates apoptosis in human osteoblasts under narrowly regulated conditions. *J Cell Physiol* 2006, 209(3):1021-1028.
12. Collins FL, Williams JO, Bloom AC, Stone MD, Choy E, Wang EC, Williams AS: Death Receptor 3 (TNFRSF25) Increases Mineral Apposition by Osteoblasts and Region Specific New Bone Formation in the Axial Skeleton of Male DBA/1 Mice. *J Immunol Res* 2015, 2015:901679.
13. Hrabal R, Chen Z, James S, Bennett HP, Ni F: The hairpin stack fold, a novel protein architecture for a new family of protein growth factors. *Nat Struct Biol* 1996, 3(9):747-752.
14. Tang W, Lu Y, Tian QY, Zhang Y, Guo FJ, Liu GY, Syed NM, Lai Y, Lin EA, Kong L *et al*: The Growth Factor Progranulin Binds to TNF Receptors and Is Therapeutic Against Inflammatory Arthritis in Mice. *Science* 2011, 332(6028):478-484.

15. Tian Q, Zhao Y, Mundra JJ, Gonzalez-Gugel E, Jian J, Uddin SM, Liu C: Three TNFR-binding domains of PGRN act independently in inhibition of TNF-alpha binding and activity. *Front Biosci (Landmark Ed)* 2014, 19:1176-1185.
16. Liu CJ: Progranulin: a promising therapeutic target for rheumatoid arthritis. *FEBS Lett* 2011, 585(23):3675-3680.
17. Liu CJ, Bosch X: Progranulin: A growth factor, a novel TNFR ligand and a drug target. *Pharmacology & therapeutics* 2012, 133(1):124-132.
18. Liu-Bryan R, Terkeltaub R: Emerging regulators of the inflammatory process in osteoarthritis. *Nature reviews Rheumatology* 2015, 11(1):35-44.
19. Feng JQ, Guo FJ, Jiang BC, Zhang Y, Frenkel S, Wang DW, Tang W, Xie Y, Liu CJ: Granulin epithelin precursor: a bone morphogenic protein 2-inducible growth factor that activates Erk1/2 signaling and JunB transcription factor in chondrogenesis. *FASEB J* 2010, 24(6):1879-1892.
20. Xu K, Zhang Y, Ilalov K, Carlson CS, Feng JQ, Di Cesare PE, Liu CJ: Cartilage oligomeric matrix protein associates with granulin-epithelin precursor (GEP) and potentiates GEP-stimulated chondrocyte proliferation. *J Biol Chem* 2007, 282(15):11347-11355.
21. Guo F, Lai Y, Tian Q, Lin EA, Kong L, Liu C: Granulin-epithelin precursor binds directly to ADAMTS-7 and ADAMTS-12 and inhibits their degradation of cartilage oligomeric matrix protein. *Arthritis Rheum* 2010, 62(7):2023-2036.
22. Zhao YP, Liu B, Tian QY, Wei JL, Richbourgh B, Liu CJ: Progranulin protects against osteoarthritis through interacting with TNF-alpha and beta-Catenin signalling. *Ann Rheum Dis* 2015, 74(12):2244-2253.
23. Xia Q, Zhu S, Wu Y, Wang J, Cai Y, Chen P, Li J, Heng BC, Ouyang HW, Lu P: Intra-articular transplantation of atsttrin-transduced mesenchymal stem cells ameliorate osteoarthritis development. *Stem cells translational medicine* 2015, 4(5):523-531.
24. Zhao YP, Tian QY, Frenkel S, Liu CJ: The promotion of bone healing by progranulin, a downstream molecule of BMP-2, through interacting with TNF/TNFR signaling. *Biomaterials* 2013, 34(27):6412-6421.
25. Wang Q, Xia Q, Wu Y, Zhang X, Wen F, Chen X, Zhang S, Heng BC, He Y, Ouyang HW: 3D-Printed Atsttrin-Incorporated Alginate/Hydroxyapatite Scaffold Promotes Bone Defect Regeneration with TNF/TNFR Signaling Involvement. *Advanced healthcare materials* 2015, 4(11):1701-1708.
26. Aggarwal BB: Editorial: Balancing tumor necrosis factor receptor I and tumor necrosis factor receptor II jointly for joint inflammation. *Arthritis & rheumatology* 2014, 66(10):2657-2660.
27. McCann FE, Perocheau DP, Ruspi G, Blazek K, Davies ML, Feldmann M, Dean JL, Stoop AA, Williams RO: Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis. *Arthritis & rheumatology* 2014, 66(10):2728-2738.
28. Zhao YP, Tian QY, Liu B, Cuellar J, Richbourgh B, Jia TH, Liu CJ: Progranulin knockout accelerates intervertebral disc degeneration in aging mice. *Scientific reports* 2015, 5:9102.
29. Olson SA, Furman BD, Kraus VB, Huebner JL, Guilak F: Therapeutic opportunities to prevent post-traumatic arthritis: Lessons from the natural history of arthritis after articular fracture. *J Orthop Res* 2015, 33(9):1266-1277.

30. Zhang Q, Lv H, Chen A, Liu F, Wu X: Efficacy of infliximab in a rabbit model of osteoarthritis. *Connect Tissue Res* 2012, 53(5):355-358.
31. Wei JL, Buza J, 3rd, Liu CJ: Does progranulin account for the opposite effects of etanercept and infliximab/adalimumab in osteoarthritis? *J Orthop Res* 2015.
32. Marsters SA, Sheridan JP, Donahue CJ, Pitti RM, Gray CL, Goddard AD, Bauer KD, Ashkenazi A: Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. *Curr Biol* 1996, 6(12):1669-1676.
33. Screaton GR, Xu XN, Olsen AL, Cowper AE, Tan R, McMichael AJ, Bell JI: LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. *Proc Natl Acad Sci U S A* 1997, 94(9):4615-4619.
34. Kitson J, Raven T, Jiang YP, Goeddel DV, Giles KM, Pun KT, Grinham CJ, Brown R, Farrow SN: A death-domain-containing receptor that mediates apoptosis. *Nature* 1996, 384(6607):372-375.
35. Wang EC, Kitson J, Thern A, Williamson J, Farrow SN, Owen MJ: Genomic structure, expression, and chromosome mapping of the mouse homologue for the WSL-1 (DR3, Apo3, TRAMP, LARD, TR3, TNFRSF12) gene. *Immunogenetics* 2001, 53(1):59-63.
36. Wang EC: On death receptor 3 and its ligands. *Immunology* 2012, 137(1):114-116.
37. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX *et al*: TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. *Immunity* 2002, 16(3):479-492.
38. Meylan F, Davidson TS, Kahle E, Kinder M, Acharya K, Jankovic D, Bundoc V, Hodges M, Shevach EM, Keane-Myers A *et al*: The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. *Immunity* 2008, 29(1):79-89.
39. Bull MJ, Williams AS, Mecklenburgh Z, Calder CJ, Twohig JP, Elford C, Evans BA, Rowley TF, Slebioda TJ, Taraban VY *et al*: The Death Receptor 3 / TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. *J Exp Med* 2008, 205(11):2457-2464.
40. Yue TL, Ni J, Romanic AM, Gu JL, Keller P, Wang C, Kumar S, Yu GL, Hart TK, Wang X *et al*: TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease. *J Biol Chem* 1999, 274(3):1479-1486.
41. Bamias G, Siakavellas SI, Stamatelopoulos KS, Chrysoschoou E, Papamichael C, Sfrikakis PP: Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. *Clinical immunology* 2008, 129(2):249-255.
42. Richard AC, Ferdinand JR, Meylan F, Hayes ET, Gabay O, Siegel RM: The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspirator. *J Leukoc Biol* 2015, 98(3):333-345.
43. Pappu BP, Borodovsky A, Zheng TS, Yang X, Wu P, Dong X, Weng S, Browning B, Scott ML, Ma L *et al*: TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. *J Exp Med* 2008, 205(5):1049-1062.
44. Al-Lamki RS, Wang J, Tolkovsky AM, Bradley JA, Griffin JL, Thiru S, Wang EC, Bolton E, Min W, Moore P *et al*: TL1A both promotes and protects from renal inflammation and injury. *Journal of the American Society of Nephrology : JASN* 2008, 19(5):953-960.

45. Osawa K, Takami N, Shiozawa K, Hashiramoto A, Shiozawa S: Death receptor 3 (DR3) gene duplication in a chromosome region 1p36.3: gene duplication is more prevalent in rheumatoid arthritis. *Genes Immun* 2004, 5(6):439-443.
46. Borysenko CW, Furey WF, Blair HC: Comparative modeling of TNFRSF25 (DR3) predicts receptor destabilization by a mutation linked to rheumatoid arthritis. *Biochem Biophys Res Commun* 2005, 328(3):794-799.
47. Takami N, Osawa K, Miura Y, Komai K, Taniguchi M, Shiraishi M, Sato K, Iguchi T, Shiozawa K, Hashiramoto A *et al*: Hypermethylated promoter region of DR3, the death receptor 3 gene, in rheumatoid arthritis synovial cells. *Arthritis Rheum* 2006, 54(3):779-787.
48. Shiozawa S, Hayashi S, Tsukamoto Y, Goko H, Kawasaki H, Wada T, Shimizu K, Yasuda N, Kamatani N, Takasugi K *et al*: Identification of the gene loci that predispose to rheumatoid arthritis. *International immunology* 1998, 10(12):1891-1895.
49. Cornelis F, Faure S, Martinez M, Prud'homme JF, Fritz P, Dib C, Alves H, Barrera P, de Vries N, Balsa A *et al*: New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. *Proc Natl Acad Sci U S A* 1998, 95(18):10746-10750.
50. Zinovieva E, Bourgain C, Kadi A, Letourneur F, Izac B, Said-Nahal R, Lebrun N, Cagnard N, Vigier A, Jacques S *et al*: Comprehensive linkage and association analyses identify haplotype, near to the TNFSF15 gene, significantly associated with spondyloarthritis. *PLoS Genet* 2009, 5(6):e1000528.
51. Konsta M, Bamias G, Tektonidou MG, Christopoulos P, Iliopoulos A, Sfikakis PP: Increased levels of soluble TNF-like cytokine 1A in ankylosing spondylitis. *Rheumatology (Oxford)* 2013, 52(3):448-451.
52. Xiu Z, Shen H, Tian Y, Xia L, Lu J: Serum and synovial fluid levels of tumor necrosis factor-like ligand 1A and decoy receptor 3 in rheumatoid arthritis. *Cytokine* 2015, 72(2):185-189.
53. Cassatella MA, da Silva GP, Tinazzi I, Facchetti F, Scapini P, Calzetti F, Tamassia N, Wei P, Nardelli B, Roschke V *et al*: Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis. *J Immunol* 2007, 178(11):7325-7333.
54. Zhang J, Wang X, Fahmi H, Wojcik S, Fikes J, Yu Y, Wu J, Luo H: Role of TL1A in the pathogenesis of rheumatoid arthritis. *J Immunol* 2009, 183(8):5350-5357.
55. Reichwald K, Jorgensen TZ, Tougaard P, Skov S: TL1A induces TCR independent IL-6 and TNF-alpha production and growth of PLZF(+) leukocytes. *PLoS one* 2014, 9(1):e85793.
56. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y *et al*: Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. *J Exp Med* 2006, 203(12):2673-2682.
57. Wang EC, Thern A, Denzel A, Kitson J, Farrow SN, Owen MJ: DR3 regulates negative selection during thymocyte development. *Mol Cell Biol* 2001, 21(10):3451-3461.
58. Jones GW, Stumhofer JS, Foster T, Twohig JP, Hertzog P, Topley N, Williams AS, Hunter CA, Jenkins BJ, Wang EC *et al*: Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. *FASEB J* 2011, 25(1):409-419.

59. Zhou M, Liu R, Su D, Feng X, Li X: TL1A increased the differentiation of peripheral Th17 in rheumatoid arthritis. *Cytokine* 2014, 69(1):125-130.
60. Wang EC, Newton Z, Hayward OA, Clark SR, Collins F, Perks WV, Singh RK, Twohig JP, Williams AS: Regulation of early cartilage destruction in inflammatory arthritis by death receptor 3. *Arthritis & rheumatology* 2014, 66(10):2762-2772.
61. Kang YJ, Kim WJ, Bae HU, Kim DI, Park YB, Park JE, Kwon BS, Lee WH: Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. *Cytokine* 2005, 29(5):229-235.
62. McLaren JE, Calder CJ, McSharry BP, Sexton K, Salter RC, Singh NN, Wilkinson GW, Wang EC, Ramji DP: The TNF-like protein 1A-death receptor 3 pathway promotes macrophage foam cell formation in vitro. *J Immunol* 2010, 184(10):5827-5834.
63. van Lent PL, Hofkens W, Blom AB, Grevers L, Sloetjes A, Takahashi N, van Tits LJ, Vogl T, Roth J, de Winther MP *et al*: Scavenger receptor class A type I/II determines matrix metalloproteinase-mediated cartilage destruction and chondrocyte death in antigen-induced arthritis. *Arthritis Rheum* 2009, 60(10):2954-2965.
64. Bu R, Borysenko CW, Li Y, Cao L, Sabokbar A, Blair HC: Expression and function of TNF-family proteins and receptors in human osteoblasts. *Bone* 2003, 33(5):760-770.
65. Lories RJ, Matthys P, de Vlam K, Derese I, Luyten FP: Ankylosing enthesitis, dactylitis, and onychoprosperiostitis in male DBA/1 mice: a model of psoriatic arthritis. *Ann Rheum Dis* 2004, 63(5):595-598.
66. Liu C, Li XX, Gao W, Liu W, Liu DS: Progranulin-derived Atsstrin directly binds to TNFRSF25 (DR3) and inhibits TNF-like ligand 1A (TL1A) activity. *PloS one* 2014, 9(3):e92743.
67. Mundra JJ, Jian J, Bhagat P, Liu CJ: Progranulin inhibits expression and release of chemokines CXCL9 and CXCL10 in a TNFR1 dependent manner. *Scientific reports* 2016, 6:21115.
68. Wei F, Zhang Y, Jian J, Mundra JJ, Tian Q, Lin J, Lafaille JJ, Tang W, Zhao W, Yu X *et al*: PGRN protects against colitis progression in mice in an IL-10 and TNFR2 dependent manner. *Scientific reports* 2014, 4:7023.
69. Wei F, Zhang Y, Zhao W, Yu X, Liu CJ: Progranulin Facilitates Conversion and Function of Regulatory T Cells under Inflammatory Conditions. *PloS one* 2014, 9(11):e112110.
70. Thurner L, Stoger E, Fadle N, Klemm P, Regitz E, Kemele M, Bette B, Held G, Dauer M, Lammert F *et al*: Proinflammatory progranulin antibodies in inflammatory bowel diseases. *Digestive diseases and sciences* 2014, 59(8):1733-1742.
71. Twohig JP, Roberts MI, Gavalda N, Rees-Taylor EL, Giralt A, Adams D, Brooks SP, Bull MJ, Calder CJ, Cuff S *et al*: Age-dependent maintenance of motor control and corticostriatal innervation by death receptor 3. *J Neurosci* 2010, 30(10):3782-3792.
72. Yin F, Dumont M, Banerjee R, Ma Y, Li H, Lin MT, Beal MF, Nathan C, Thomas B, Ding A: Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. *Faseb J* 2010, 24(12):4639-4647.
73. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. *Gastroenterology* 2003, 124(7):1774-1785.

74. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. *N Engl J Med* 2001, 345(15):1098-1104.
75. Thurner L, Preuss KD, Fadle N, Regitz E, Klemm P, Zaks M, Kemele M, Hasenfus A, Csernok E, Gross WL *et al*: Progranulin antibodies in autoimmune diseases. *Journal of autoimmunity* 2013, 42:29-38.
76. Thurner L, Fadle N, Regitz E, Kemele M, Klemm P, Zaks M, Stoger E, Bette B, Carbon G, Zimmer V *et al*: The molecular basis for development of proinflammatory autoantibodies to progranulin. *Journal of autoimmunity* 2015, 61:17-28.
77. Kitaura H, Kimura K, HKohara H, Yoshimatsu M, Takano-Yamamoto T: Immunological Reaction in TNF- α -Mediated Osteoclast Formation and Bone Resorption *In Vitro* and *In Vivo*. *Clin Dev Immunol* 2013, 2013:181849.
78. Robinson LJ, Borysenko CW, Blair HC: Tumor necrosis factor family receptors regulating bone turnover: new observations in osteoblastic and osteoclastic cell lines. *Ann NY Acad Sci* 2007, 1116:432-443.
79. Croft M, Benedict CA, Ware CF: Clinical targeting of the TNF and TNFR superfamilies. *Nat Rev Drug Discov* 2013, 12(2):147-168.
80. Hashimoto H, Tanaka M, Suda T, Tomita T, Hayashida K, Takeuchi E, Kaneko M, Takano H, Nagata S, Ochi T: Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. *Arthritis Rheum* 1998, 41(4):657-662.
81. Martinez-Lorenzo MJ, Anel A, Saez-Gutierrez B, Royo-Canas M, Bosque A, Alava MA, Pineiro A, Lasiera P, Asin-Ungria J, Larrad L: Rheumatoid synovial fluid T cells are sensitive to APO2L/TRAIL. *Clinical immunology* 2007, 122(1):28-40.
82. Wang L, Liu S, Zhao Y, Liu D, Liu Y, Chen C, Karray S, Shi S, Jin Y: Osteoblast-induced osteoclast apoptosis by fas ligand/FAS pathway is required for maintenance of bone mass. *Cell Death Differ* 2015, 22(10):1654-1664.
83. Seidel MF, Herguijuela M, Forkert R, Otten U: Nerve growth factor in rheumatic diseases. *Seminars in arthritis and rheumatism* 2010, 40(2):109-126.
84. Shiozawa K, Hino K, Shiozawa S: Alternatively spliced EDA-containing fibronectin in synovial fluid as a predictor of rheumatoid joint destruction. *Rheumatology (Oxford)* 2001, 40(7):739-742.
85. Audo R, Calmon-Hamaty F, Baeten D, Bruyer A, Combe B, Hahne M, Morel J: Mechanisms and clinical relevance of TRAIL-triggered responses in the synovial fibroblasts of patients with rheumatoid arthritis. *Arthritis Rheum* 2011, 63(4):904-913.
86. Colucci S, Brunetti G, Cantatore FP, Oranger A, Mori G, Pigantaro P, Tamma R, Grassi FR, Zallone A, Grano M: The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. *Apoptosis* 2007, 12:1623-1632.
87. Xia WF, Jung JU, Shun C, Xiong S, Xiong L, Shi XM, Mei L, Xiong WC: Swedish mutant APP suppresses osteoblast differentiation and causes osteoporotic deficit, which are ameliorated by N-acetyl-L-cysteine. *J Bone Miner Res* 2013, 28(10):2122-2135.
88. Wu H, Siegel RM: Progranulin Resolves Inflammation. *Science* 2011, 332(6028):427-428.

Table 1 Cellular expression of death domain containing TNFRSF members and their association with arthritis

Receptor	Ligand	Association with arthropathies	Osteoblast	Osteoclast	Osteocyte	Fibroblasts-like synoviocytes	Chondrocytes	Leukocyte subsets	References
TNFR1 (TNFRSF 1A)	TNF α (TNFSF 2) LT α (TNFSF 1) PGRN	RA, OA, SA, Arthropathies	✓	✓	✓	✓	✓	All	[2-6, 14, 77, 78]
Fas (TNFRSF 6)	FASL (TNFSF 6)	RA OA Arthropathies	✓	✓	✓	✓	✓	All	[79-82]
NGFR (TNFRSF 16)	NGF	RA OA SA Arthropathies	✓	✓	X	X	X	T cells	[2, 79, 83]
EDAR (TNFRSF 27)	EDA	RA Arthropathies	X	X	X	X	X	Macrophage subsets	[84]
DR3 (TNFRSF 25)	TL1A (TNFSF 15) PGRN	RA OA SA Arthropathies	✓	✓	X	X	X	CD4+ T, Treg, CD8+ T cells, B cell subset, macrophages (inducible),	[10-12, 37, 51, 78]

DR4 (TNFRSF 10A)	TRAIL (TNFSF 10)	RA	✓	✓	X	✓	✓	neutrophils Activated T cells	[78, 79, 85, 86]
		OA							
		SA							
		Arthropathies							
DR5 (TNFRSF 10B)	TRAIL (TNFSF 10)	RA	✓	✓	X	✓	✓	All	[78, 85, 86]
		OA							
		SA							
		Arthropathies							
DR6 (TNFRSF 21)	APP	X	APP	APP	X	X	✓	T cells, B cells, dendritic cells	[87]

Table 2 Summary of key points about Progranulin and TNFR and DR3 pathways in rheumatoid arthritis, osteoarthritis, spondyloarthritis and other arthropathies

#	Key points	References
1.	<p><u>Progranulin (PGRN)</u></p> <ul style="list-style-type: none"> • also known as granulins-epithelin precursor (GEP), proepithelin, acrogranin, and GP88/PC-cell derived growth factor (PCDGF) • 593-amino-acid autocrine growth factor • seven-and-a-half repeats of a cysteine-rich motif • Involved in: embryogenesis, wound healing antiinflammatory, host defense, neurotrophic factor • High PGRN levels associated with several human cancers 	[14, 16, 17]
2.	<p><u>PGRN ligand of TNFR1, TNFR2 and DR3</u></p> <ul style="list-style-type: none"> • PGRN ligand of TNFR1, TNFR2 and DR3 and physiologic antagonist of TNF-α, LTα and TL1a • Inhibition of TNFR1 and DR3 pathways, but activation of TNFR2 pathway by PGRN • 600 times higher affinity towards TNFR2 by PGRN compared to TNF-α • PGRNs affinity to TNFR1, TNFR2 and DR3 originates from granulins F, A and C with linker regions • Atstrin: smallest recombinant derivate of PGRN synthesized of granulins F, A, C and linker regions P3, P4 and P5 of PGRN with preserved antiinflammatory effect • PGRN attenuates TNF-α induced downmodulation of CD4⁺CD25^{hi} FOXP3⁺Tregs • PGRN stimulates conversion of CD4⁺CD25⁻ T cells into induced Tregs (iTregs) 	[14, 66, 69]
3.	<p><u>PGRN, TNFR1 and TNFR2 in Osteoarthritis</u></p> <ul style="list-style-type: none"> • low PGRN levels -> spontaneous OA • high PGRN levels -> anabolic function • catabolic effect of TNF-α mainly mediated via TNFR1 • TNFR2 pathway anti-inflammatory & osteoprotective • administration of sTNFR2/Fc fusion protein neutralizes TNF-α and PGRN and leads to exaggeration of OA • administration of Anti-TNF-α Mabs neutralizes TNF-α specifically and ameliorates OA • PGRN account for the opposite effects of sTNFR2/Fc fusion protein and Anti-TNF-α Mabs 	[30, 31]
4.	<p><u>TL1a/DR3</u></p> <ul style="list-style-type: none"> • High levels of TL1A induce TH17 response in RA • DR3^{-/-} mice resistant of cartilage destruction in AIA • CIA exaggeration by TL1a, amelioration by Anti-TL1a Mab • TL1a/DR3 activation induces MMP9 and CCL3 	[52, 59] [60] [39]

-
- DcR3 decoy ligand for TL1A, FasL and LIGHT not in mice -> results from mouse models difficult to translate
-

5. **pSer81 PGRN and PGRN antibodies**

- Neutralizing PGRN antibodies directed against the N-terminal 112AA occur frequently in various autoimmune diseases [5] [75, 76]
 - PGRN antibodies are induced by a second, transiently occurring hyperphosphorylated PGRN isoform (pSer81 PGRN)
 - pSer81 PGRN lacks affinity for TNFR1, TNFR2 and DR3 and thus antagonism of TNF- α and TL1a
 - -> dysbalance of proinflammatory TNF- α & TL1A and antiinflammatory functional PGRN in various inflammatory diseases
-

6. **Clinical Perspective**


- Targeting of TNFR/TNF superfamily common therapeutic strategy [79]
 - Possible advantages of rec. PGRN/Atstrin compared to conventional TNF-blockers due to additional inhibition of DR3 and activation of TNFR2
 - PGRN-autoantibodies regularly target the N-terminal 112 AA and thus not the parts constitutive for Atstrin; however affinity has not been excluded
 - Risk of side effects concerning susceptibility to infectious diseases, emergence of new autoimmune phenomena or cancer remain unclear
-

Figure Legend

Fig. 1. A) Domain Structure and Organization of PGRN and Atsttrin. PGRN consists of 7½ repeats of a cysteine-rich granulin motif in the order of P-G-F-B-A-C-D-E, where A to G are full repeats, and P is the half motif. Atsttrin, derived from PGRN, consists of three half units of granulins A, C and F, and their accompanying linker regions. B) A proposed models for explaining the independent action of three TNFR-binding domains of PGRN. TNF α trimers binds to receptors in a heterohexameric 3:3 complex[88]. The three fragments of Atsttrin act independently for interacting with TNFR, and changing the order of these fragments does not affect the ability to binding to TNFR[15]. It is proposed that each TNFR-binding domain may function as a single TNF α molecule, and the intact Atsttrin might resemble a TNF trimer through internal folding at their linker regions.

Fig. 2. A proposed model illustrating the multiple signaling pathways by which PGRN (and its derivative Atsttrin) exerts its protective actions in autoimmunity. PGRN (Atsttrin) binds to TNF receptor 2 (TNFR2) and stimulates the formation and function of Tregs, but may antagonize TL1A/DR3 signaling in these cells. PGRN (Atsttrin) also antagonizes TNF/TNFR1 and TL1A/DR3 signaling and inhibits their inflammatory activities.

Fig. 3. A) Balance of TNF- α & TL1A and their antagonist progranulin in a healthy control. B) Dysbalance of proinflammatory TNF- α & TL1A and antiinflammatory PGRN due to overexpression of proinflammatory TNF- α & TL1A and diminished antagonistic effects of PGRN due to hyperphosphorylation of Ser81 of PGRN and induction of neutralizing PGRN-antibodies.



254x190mm (300 x 300 DPI)

Accept




Fig. 2

279x215mm (300 x 300 DPI)

Accepted




Fig. 3

279x215mm (300 x 300 DPI)

Accepted